PHAR · Pharming Group N.V.

Summary

Pharming announced presentations at the CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID.

Key takeaways

• Interim long-term extension study data for leniolisib in pediatric APDS patients aged 4-11 years will be presented.
• Clinical experience data from expanded access use of leniolisib in CVID and CVID-like disorders will be shared.
• Two phase II trials (NCT06897358, NCT06549114) are evaluating leniolisib in CVID and PIDs with immune dysregulation.
• Leniolisib is approved for APDS in the U.S., U.K., Australia, Israel (≥12 years) and Japan (≥4 years).
• Regulatory review for leniolisib in APDS is ongoing in Canada and other countries.